Guilin Sanjin Pharmaceutical Co., Ltd. (SZSE: 002275)
Health Care · Pharmaceuticals · CN
CN¥13.23
-0.75% today · -14.9% 1Y
Guilin Sanjin Pharmaceutical Co., Ltd. (SZSE: 002275) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.16B and employs 2,563 people.
Over the last twelve months the share price has lost 14.9%, trading between 11.91 and 15.75.
Tweenvest scores Guilin Sanjin Pharmaceutical Co., Ltd. across four factors: quality 85/100, value 84/100, growth 43/100, dividend 90/100. Its strongest factor is dividend.
002275 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.16B
- Revenue (TTM)
- $296.78M
- P/E
- 19.14
- EPS
- 0.69
- Dividend yield
- 3.78%
- Beta (5Y)
- 0.17
- 52-week high
- CN¥15.75
- 52-week low
- CN¥11.91
- Avg volume (3M)
- —
- Shares outstanding
- 587.57M
- Employees
- 2,563
- Next earnings
- —
About Guilin Sanjin Pharmaceutical Co., Ltd.
Guilin Sanjin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the research, production, and distribution of traditional Chinese and natural medicines across China. Established in 1967 and headquartered in Guilin, the company's product portfolio prominently features well-known traditional Chinese medicine (TCM) brands such as Guilin watermelon frost and lozenge, Sanjin tablets, and Naomaitai capsules. Beyond these core offerings, it also manufactures a range of other TCM preparations. The company operates as a subsidiary of the broader Guilin SanJin Group Co.,Ltd.
- ISIN
- CNE100000DY9
- Founded
- 2001
- Listed since
- Jul 10, 2009
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.